The New South Wales Supreme Court has declined in popularity as a venue for class action litigation since contingency fees were introduced in Victoria, according to a new report.
A judge has approved a $50.45 million settlement in a class action by family members and deceased estates of the Northern Territory Stolen Generations. He has also approved a 13 per cent funding commission by way of a common fund order, saying debates about CFOs had become “lost in the label”.
The Australian Securities and Investments Commission is fighting a challenge by three KordaMentha partners to the regulator’s decision to allow insurer Atradius to subject them to public examination over their administration of failed steel giant Arrium.
The former dean of art school LCI Melbourne is seeking over $860,000 in compensation in a case alleging she was unfairly sacked via Instagram direct message because she took paid annual leave during “the most important term of the year”.
The authorised representative of forex broker Union Standard can’t exclude parts of an opinion by an ASIC-appointed expert in a case alleging it traded in margin products with Chinese clients despite knowing it was illegal under Chinese law.
KPMG has hit back at a shareholder class action over allegedly misleading statements made ahead of CuDeco’s collapse in 2020, placing blame on the defunct mining company, its directors and group members themselves.
Construction firm CIMIC has won its bid to view identifying information about institutional investors in a shareholder class action, despite the applicant’s claims it could deter group members from signing on to the case.
A judge has granted a discovery bid by two of Gina Rinehart’s children as a long-running fight over ownership of a valuable mining tenement nears trial, and has rejected her company’s argument that they were solely responsible for dragging out a dispute over documents.
Carnival has won its bid to strike out a class action over norovirus outbreaks on its Sun Princess cruise ship.
Bayer told a jury that clinical trials from the 1990’s to 2014 showed its Essure birth control device was “safe and efficacious”, as the pharmaceutical giant faces trial in a class action by patients who claim they suffered debilitating injuries from the device.